Mitral Valve Area Calculator
Calculate mitral valve area quickly with our cardiovascular system tool. Get results based on evidence-based formulas with clear explanations.
Formula
MVA = 220 / PHT (Hatle); MVA = Flow / (37.7 x sqrt(Mean Gradient)) (Gorlin)
The Pressure Half-Time method uses the empirical constant 220 divided by the pressure half-time in milliseconds. The Gorlin formula calculates flow rate as (CO x 1000) / (DFP x HR), then divides by the hydraulic constant 37.7 multiplied by the square root of the mean gradient. Both yield valve area in square centimeters.
Worked Examples
Example 1: Moderate Mitral Stenosis Assessment
Problem: A patient with rheumatic heart disease has a Doppler pressure half-time of 180 ms, mean gradient of 8 mmHg, CO of 4.5 L/min, HR 75, and DFP of 0.45s. Calculate MVA.
Solution: PHT Method:\nMVA = 220 / PHT = 220 / 180 = 1.22 cm2\n\nGorlin Formula:\nFlow = (CO x 1000) / (DFP x HR) = (4500) / (0.45 x 75) = 133.3 mL/s\nMVA = 133.3 / (37.7 x sqrt(8)) = 133.3 / 106.6 = 1.25 cm2\n\nBoth methods indicate moderate mitral stenosis.
Result: MVA: 1.22 cm2 (PHT) / 1.25 cm2 (Gorlin) | Severity: Moderate | Mean Gradient: 8 mmHg
Example 2: Severe Mitral Stenosis Evaluation
Problem: A symptomatic patient has PHT of 280 ms, mean gradient of 15 mmHg, CO of 3.8 L/min, HR 88, DFP 0.38s. Calculate MVA and assess severity.
Solution: PHT Method:\nMVA = 220 / PHT = 220 / 280 = 0.79 cm2\n\nGorlin Formula:\nFlow = (3800) / (0.38 x 88) = 113.6 mL/s\nMVA = 113.6 / (37.7 x sqrt(15)) = 113.6 / 146.0 = 0.78 cm2\n\nBoth methods confirm severe stenosis requiring intervention.
Result: MVA: 0.79 cm2 (PHT) / 0.78 cm2 (Gorlin) | Severity: Severe | Intervention indicated
Frequently Asked Questions
What is mitral valve area and why is it important in cardiac assessment?
Mitral valve area (MVA) refers to the effective orifice area of the mitral valve through which blood flows from the left atrium to the left ventricle during diastole. The normal mitral valve area is 4-6 square centimeters, and stenosis occurs when this area is reduced by scarring, calcification, or commissural fusion. MVA is the primary parameter used to grade the severity of mitral stenosis: mild stenosis is defined as MVA greater than 1.5 square centimeters, moderate as 1.0-1.5, and severe as less than 1.0. Accurate MVA measurement is critical because it directly determines the need for intervention, whether percutaneous mitral balloon commissurotomy or surgical valve replacement. The valve area also correlates with symptoms, pulmonary hypertension severity, and long-term outcomes.
How does the Pressure Half-Time method calculate mitral valve area?
The Pressure Half-Time (PHT) method, developed by Hatle and colleagues, uses Doppler echocardiography to estimate MVA. The pressure half-time is defined as the time required for the transmitral pressure gradient to decrease to half its initial peak value. It is measured from the Doppler E-wave deceleration slope of mitral inflow. The empirical formula MVA = 220/PHT was derived from correlation studies with invasive catheterization data. A PHT of 220 milliseconds corresponds to an MVA of 1.0 square centimeter (severe stenosis), while a PHT of 110 milliseconds corresponds to 2.0 square centimeters (mild stenosis). This method is widely used because it is relatively independent of heart rate and flow conditions, though it can be inaccurate immediately after balloon valvuloplasty or in patients with significant aortic regurgitation.
What are the main causes of mitral stenosis worldwide?
Rheumatic heart disease remains the most common cause of mitral stenosis globally, accounting for the vast majority of cases especially in developing countries. Rheumatic fever causes inflammation and scarring of the valve leaflets, leading to commissural fusion, leaflet thickening, chordal shortening, and calcification over years to decades. In developed countries where rheumatic fever has become less common, degenerative calcific mitral stenosis in elderly patients is increasingly recognized. Other less common causes include congenital mitral stenosis (parachute mitral valve, supravalvular ring), systemic lupus erythematosus, carcinoid heart disease, and radiation-induced valvulopathy. Mitral annular calcification can also cause functional stenosis in elderly patients. The worldwide burden of rheumatic mitral stenosis remains enormous, with an estimated 33 million people affected globally.
How does mitral stenosis lead to pulmonary hypertension?
Mitral stenosis creates a pressure gradient between the left atrium and left ventricle, causing progressive left atrial pressure elevation. As left atrial pressure rises, it is transmitted retrograde to the pulmonary veins, leading to pulmonary venous hypertension. Initially, this causes pulmonary congestion and dyspnea on exertion. Over time, chronically elevated pulmonary venous pressure triggers reactive vasoconstriction of the pulmonary arterioles (reactive pulmonary hypertension), which further increases pulmonary arterial pressure beyond what passive transmission alone would produce. Eventually, structural remodeling of the pulmonary vasculature occurs, including intimal fibrosis and medial hypertrophy, leading to fixed pulmonary hypertension that may not fully reverse even after successful mitral valve intervention. The degree of pulmonary hypertension correlates with symptom severity and is an important factor in timing intervention.
What is percutaneous mitral balloon commissurotomy and who is a candidate?
Percutaneous mitral balloon commissurotomy (PMBC), also known as balloon mitral valvotomy, is a catheter-based procedure that splits fused mitral valve commissures using an inflatable balloon. The procedure is performed via transseptal puncture, advancing a balloon catheter across the atrial septum and positioning it across the stenotic mitral valve. Inflation of the balloon splits the fused commissures, increasing the effective valve area. Ideal candidates have pliable, non-calcified valves with commissural fusion and no significant mitral regurgitation, assessed using the Wilkins echocardiographic scoring system. Patients with Wilkins scores of 8 or below typically have excellent results, with valve area increases from approximately 1.0 to 2.0 square centimeters. PMBC is the procedure of choice for symptomatic severe mitral stenosis with favorable valve morphology, achieving results comparable to surgical commissurotomy with lower morbidity.
How do symptoms of mitral stenosis correlate with valve area measurements?
The relationship between mitral valve area and symptoms follows a generally predictable pattern, though individual variation exists. Patients with mild stenosis (MVA greater than 1.5 square centimeters) are typically asymptomatic at rest but may develop dyspnea during vigorous exercise or conditions that increase heart rate. Moderate stenosis (MVA 1.0-1.5 square centimeters) usually causes symptoms with moderate exertion such as climbing stairs or brisk walking, and patients may develop atrial fibrillation. Severe stenosis (MVA less than 1.0 square centimeters) causes symptoms at rest or with minimal activity, including dyspnea, orthopnea, and fatigue. However, symptoms can be precipitated at any valve area by conditions that increase heart rate or cardiac output, such as exercise, pregnancy, fever, anemia, or new-onset atrial fibrillation, because shortened diastolic filling time increases the transmitral gradient.